The incidence of immune-effector-cell-related neurotoxicity syndrome is closely correlated with CRS; it is more common in patients with B-ALL than in those with other diseases that receive CD19-specific CART-cell therapy [40,41]. Here, CD19 is linked to acute lymphoblastic leukemia.